News Hub | News Direct

Green Cubes Technology Expands Executive Team

Green Cubes Technology

Green Cubes Technology, a leader in electrification and clean, connected, cost-effective power solutions, today announced four significant executive appointments to its leadership team - Ken Gregory as Vice President of Supply Chain and Procurement, Alan Forster as Vice President of Sales for Americas, Rita Faunce as Vice President of Sales Operations and Customer Experience, and Rocio Castellanos as International Controller. These executives join Ken Johnson, who was appointed Chief Operating Officer (COO) last year. The team will provide leadership to sales, supply chain, operations, manufacturing, and customer support functions for continued growth within Motive (including Ground Support & Materials Handling), Stationary (Telecom & Data Center), and Mobile (Industrial Automation) Power market segments. “We’re very pleased to add so many talented professionals to Green Cubes’ executive team,” said Keith Washington, CEO of Green Cubes Technology. “This reflects the rapid growth of the company, and the leadership that each of these individuals bring to the company will help us continue to lead the charge to electrification.” Mr. Gregory has a history of success with enterprise operations and transformation, customer experience, supply chain and channel/alliance sales across enterprise and consumer Information Technology, Education and Learning organizations. He has driven sustainable cultural and digital transformations in highly matrixed organizations resulting in increased revenue, enhanced customer confidence, organizational capability, and employee engagement. He brings over 25 years of core supply chain experience gained at IBM supporting its enterprise computer hardware segments. Mr. Gregory’s most recent experiences were at Pearson, a global leader in learning and education where he oversaw customer service and digital operations transformation. Mr. Forster is responsible for managing and accelerating Green Cubes’ pipeline and revenue growth while developing its channel and sales enablement programs. In his recent role as Sales Director for the company’s Telecom and Data Center business unit (operating as Unipower), he helped rebuild sales and channel relationships, managed consistent quarterly growth, and increased sales channel coverage during the global pandemic. By working diligently with the Unipower team, he doubled bookings and revenue during a global supply chain and transportation slow down. Ms. Faunce directs Green Cubes’ sales operations teams globally, drives its customer experience strategy, and will facilitate ownership of customer experience excellence. She has vast experience managing global teams in sales operations, customer service, and customer satisfaction with success in delivering customer facing programs that foster a spirit of transparency, continuous improvement, and mutual accountability in customer relationships. Ms. Faunce will implement continuous improvement plans, leverage customer insights and data, and work across multiple departments to ensure team members and leadership are aware of and dedicated to the goals of continuously improving the customer experience. Ms. Castellanos joins Green Cubes as a key member of the global finance and accounting team. She is responsible for the internal and external financial reporting of all Green Cubes affiliated entities outside the U.S. In her role, she will support the entities in financial reporting topics and bridge the information to the U.S. headquarters. She will focus on continuous improvement of processes and deliverables to enhance financial performance visibility across the entities, as well as act as a strategic business advisor for International Operations. Ms. Castellanos brings over 20 years of experience and has worked for various companies including PwC, Swiss Life and Daniel Swarovski Corp. The expansion of Green Cubes’ executive team follows the company’s announcement last year that it added a second 36,000 square foot domestic facility in Kokomo, Indiana, and expanded its product lines for Motive and Stationary Power to support accelerated growth in Material Handling and Telecom markets. The Kokomo facility is currently increasing its manufacturing throughput and is expecting a 150% increase in Motive Power shipments in 2022, relative to 2021. Additionally, Green Cubes previously announced that it established two new facilities in Europe and a Technology Center in Zurich, Switzerland. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With a global footprint across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information at https://greencubes.com/. Contact Details Ray Young +1 512-633-6855 ray@razorsharppr.com Company Website https://greencubestech.com/

May 19, 2022 09:00 AM Eastern Daylight Time

G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues

G Medical Innovations Holdings

Irvine, CA – May 18, 2022 – G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company”), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022. While the Company is still working on finalizing most of the revenue figures for the first quarter, the previously reported purchase orders received by the Company from McDade Products, LLC for 6 million co-branded LiveNow COVID-19 PCR Test Collection Kits (approximately $20 million in orders) have not materialized into revenues due to a slowdown of the pandemic in the US during the first quarter. Approximately $6 million of invoices have been submitted for payment, out of which $0.7 million has been received and another batch of claims of approximately $1 million is to be filed for payment. Further, the proposed budget for COVID-19 tests which has not yet been approved by the U.S. Congress creates further uncertainty as to revenue the Company expected to receive and recognize from sales of such tests in its testing centers. The Company plans to announce the final revenues numbers for the first quarter of 2022 as part of its financial results release for the first six months of 2022. The Biden administration has announced that it expects another outbreak of the pandemic as early as this fall with new variants and expects about 100 million patients, which we believe will increase the need for tests. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward looking statement in this press release when it is providing an update regarding its forecast for first quarter 2022 revenue in connection with the previously reported purchase orders, uncertainty of additional government funding for COVID-19 tests and the belief in an increased need for COVID-19 testing in the future. Because such actions deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of the Company could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 29, 2022, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

May 18, 2022 04:05 PM Eastern Daylight Time

Kadimastem Expands R&D Program to Include Multiple Sclerosis

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). Kadimastem remains on track to submit IND to the FDA before the end of 2022 to begin a multicenter clinical trial of AstroRx® for ALS in 2023 in the U.S. As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services and Development Ltd. Hadasit is the technology transfer arm of Hadassah Medical Center. It is well known for its partnerships with international companies and research institutions, and its success with groundbreaking medical developments that fill unmet market needs. Under the terms of the agreement, Kadimastem’s astrocyte cells, which comprise AstroRx®, the company’s flagship product for ALS, will be tested for their therapeutic potential for MS using a unique animal model in Professor Tamir Ben-Hur’s laboratory at Hadassah Medical Center. Professor Ben-Hur is the Director of Brain Medicine at Hadassah Ein Kerem Medical Center and a pioneer and opinion leader in the field of clinical research in multiple sclerosis. If successful, the goal is to thereafter plan and conduct a clinical trial of AstroRx® for MS. "We are very excited about the expansion of the range of neurological diseases that astrocyte cells (AstroRx®) could be used to treat. The pre-clinical study that will be conducted at Professor Ben-Hur's laboratory is extraordinary. It’s a first-of-its-kind in the world to treat multiple sclerosis, " said Professor Michel Revel, Israel Prize Winner, Kadimastem Founder and Chief Scientist, and famous for his groundbreaking research that led to the development of the blockbuster drug Rabif for multiple sclerosis. Kadimastem CEO Asaf Shiloni said, “Expanding our R&D activity by conducting the ALS and the MS research in parallel enables us to provide maximum value for patients and investors alike. We are working diligently to move the ALS clinical program ahead. We also hope that AstroRx® will be the answer for the millions of MS patients for whom the usual method of treatment is ineffective. The use of AstroRx® cells, with their various mechanisms of action, may lead to an innovative regenerative treatment for the disease." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1613 a.shiloni@kadimastem.com Company Website https://www.kadimastem.com/

May 18, 2022 07:00 AM Eastern Daylight Time

Image

BreatheSuite Announces Latest Addition to Board of Directors

BreatheSuite

BreatheSuite Inc., a Canadian connected respiratory health company, today announced that Brad Fluegel officially joined the company’s Board of Directors. In his role, Fluegel will tap into his extensive digital health experience to provide feedback on how to support the company’s growth. “We welcome Brad to the BreatheSuite Board of Directors and look forward to leveraging his knowledge and experience in digital health as we continue to expand the BreatheSuite program,” said Brett Vokey, CEO of BreatheSuite. “We are excited to draw upon his background in commercial healthcare as we continue to work toward improving the lives of respiratory patients worldwide. Brad has exactly the experience we need to navigate the digital health ecosystem.” Before working as an advisor to healthcare organizations, entrepreneurs, and other participants in healthcare, Fluegel was most recently the senior vice president and chief healthcare commercial market development officer for Walgreen Co. based in Deerfield, Ill. He was responsible for all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Previously, he was chief strategy and business development officer for Walgreens, responsible for corporate strategy and business development. Prior to joining Walgreens, Fluegel served as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies. While at Wellpoint, Fluegel was responsible for long-term strategic planning, government affairs, corporate communications including public relations, corporate marketing, corporate development, international expansion, innovation and new business ventures. Fluegel was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market. “I’m excited to join BreatheSuite, as digital healthcare has always been a passion of mine because of its ability to improve people’s lives,” said Fluegel. “I look forward to using my experience to help BreatheSuite achieve its mission to provide better, more transparent care for all people with asthma or COPD.” Fluegel is well versed in the complexities of business and healthcare and is also a lecturer at the University of Pennsylvania’s Wharton School of Business. He earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a Bachelor of Arts in business administration from the University of Washington. He serves on the Board of Directors of MJHS Health System in New York City, Performant Financial Corporation and Premera Blue Cross, among others. He was also on the board of Fitbit before its sale to Google in early 2021. Fluegel’s appointment to BreatheSuite’s Board of Directors comes on the heels of BreatheSuite’s Chief Scientific Officer, Dr. Meshari F. Alwashmi, joining the Forbes Technology Council. The company also recently announced that it secured a spot on the inaugural Canadian Business New Innovators List. About BreatheSuite BreatheSuite is a Canadian connected health company empowering people with chronic respiratory conditions live longer, healthier lives. The BreatheSuite program incorporates a smart inhaler sensor designed to track and train proper inhaler usage, a BreatheSuite App to gamify getting Asthma & COPD under control, as well as health coaches to support patients wherever they are on their journey. BreatheSuite works with leading partners across North America to deliver better care to people with chronic respiratory conditions. For more information visit www.breathesuite.com or contact info@BreatheSuite.com. Follow us on Twitter, and LinkedIn Contact Details SVM Public Relations Erin O’Brien +1 401-490-9700 erin.obrien@svmpr.com Company Website https://www.breathesuite.com/

May 17, 2022 10:00 AM Eastern Daylight Time

Underline Science Closes Pre-Series A Round To Further Advance Scholarly Research With The Growth Of The Digital Video Library

Underline Science Inc

Most industries have progressed from paper to all forms of content; how is it that one of our most essential industries, science, is staying behind. This is something Underline's founder doesn't understand, and therefore he will change it with the launch of the Underline Digital Video Library (DVL). With a considerable track record, this multi-accomplished founder is now taking on the big publishers in a way that hasn't been seen before as a premier aggregator of streaming scientific conference lecture video content. Together with his team of industry leaders, Underline is aiming to transcend the industry into the 21st century. The mission of Underline is to improve researchers' access to quality scientific conference lecture video content. Historically, if you did not attend a scientific conference, you would miss out on all of the conference's lectures. Underline's DVL contains 26,000+ videos (Health Sciences, Life Sciences, Engineering, Technology, Social Sciences, and Humanities). The video content from the world's prestigious scientific societies and universities, like IEEE, Endocrine, AIP, lecturers from MIT, Harvard, Facebook, Google, etc. Each video is complete with abstract, English transcription, bio, picture of the author, and most importantly, a DOI (digital object identifier), which ensures that the video can be searched and discovered. Today, the company announced that it had raised a $2.5 million Pre-Series A round of funding, led by South Central Ventures and the Dutch Founders Fund. As a result, Mr. Jure Mikuz (South Central Ventures) and Mr. Laurens Groenendijk (Dutch Founders Fund) will join the Underline Board of Directors. "With this new round of funding, we'll be able to enhance the Underline DVL features and content greatly. Further to grow the team and expand our go-to-market strategy," Underline CEO and founder Alex Lazinica said in a press release. "We are looking forward to increasing our penetration into the library, government and corporate, institutional subscription market." South Central Ventures, who led the round, Managing Partner Jure Mikuz, said, “Underline’s mission resonates with us very well as they are addressing a global opportunity of creating a library of global scientific video content. I believe they will be successful by facilitating their excellent execution skills and deep industry knowledge. We are very excited to join Underline on this journey.” Founding Partner Laurens Groenendijk of The Dutch Founders Fund states, " We believe that if Underline Science manages to tap into the apparent possible network effects, it can quickly grow to be the dominant player in science content aggregation. We at Dutch Founders hope to see “underlining become a verb”. If anyone is going to do it, We know a seasoned entrepreneur like Alex is. “ Underline's business model is an annual subscription fee for unlimited access to the entire Digital Video Library for the subscribing institution's community. About Underline Science Underline is the premier virtual conference platform for events in science, medicine, academia, and other professional fields. Underline’s mission is to capture and disseminate scientific knowledge through video, making it globally accessible by enriching and preserving both virtual and hybrid conference content. Underline’s groundbreaking scientific Digital Video Library is providing new opportunities to access and expand the scientific record and accelerate scientific discovery. For more information, visit the Underline website and follow Underline on Twitter. About South Central Ventures South Central Ventures is a VC investor with the longest presence in the Balkans. Operating out of four offices – Ljubljana, Zagreb, Belgrade and Skopje – the team has invested in about 40 early stage tech companies and has been an integral part of the local start up communities. With a strong base of international investors, South Central Ventures is a go-to investor for regional tech companies competing in global markets. SCV’s portfolio companies include Cognism, Celtra, Agrivi, Orgnostic and AdScanner, among others. About Dutch Founders Fund DutchFounders is an early-stage venture capital fund from Amsterdam, started by a group of successful Dutch entrepreneurs like Laurens Groenendijk (Just Eat, Treatwell, Miinto, Hiber), Patrick Kerssemakers (fonQ), Bas Beerens (WeTransfer), Hidde Hoogcarspel (Spacebuzz) and Remco van Zanten ( Booking, Zalando, Vinted and BCG). The fund specialises in marketplaces and companies with strong network effects. Since its launch in 2018, the fund has successfully invested in 16 companies. This includes: YourCampus, Shypple, Vintage Cash Cow, Lumaly, Blanco, Nostics, Reveall, Veylinx, Wonderkind, Voicebooking, Fleks, Minimum, Caya, Winc Academy, Buildstream and Tracedock (exited to CM.com). The total fund has almost €100 million assets under management. DutchFounders is a committed partner of Techleap’s Fundright initiative. ### Contact Details Underline Science, Inc. Darrell W Gunter +1 973-454-3475 darrell@underline.io Company Website https://www.underline.io/

May 17, 2022 09:30 AM Eastern Daylight Time

AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.

Appyea

AppYea (OTC: APYP) announced that its subsidiary SleepX, which focuses on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring – has signed new commercialization agreement for two additional patents by Ben-Gurion University. The new patented technology enables the innovative detection of sleep apnea and hypopnea through speech analysis using only a smartphone and with no physical contact. This is compared to traditional technologies that use physical sensors to detect apnea in overnight sleep labs. "In recent years we see a growing number of major players taking development efforts in the field of sleep monitoring and sleep apnea”, said Boris (Bary) Molchadsky, chairman & CEO of AppYea. “We are developing our own products that cater to this market while increasing our patent portfolio and examining synergistic technologies as part of our strategy to become a leading player in the sleep health market while also offering licensing agreements for leading smartphone manufacturers.” SleepX is a research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. SleepX focuses its activities on the development and commercialization of its flagship product SleepX PRO solution which is designed to diagnose sleep apnea using only a smartphone and with no physical contact. The company recently announced that it has applied to the Helsinki Committee for approval to begin its planned clinical trial on the SleepX PRO application. This trial is intended to take place at a hospital sleep lab as the first step toward applying for an FDA approval under the first-of-its-kind medical device category for “contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep”. As far as SleepX is aware, the global sleep apnea devices market size is valued at USD 3.7 billion as of 2020 with a 6.2% CAGR, reaching USD 6.1 billion by 2028, according to Grand View Research’s report. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop and market our products, the effectiveness of the Registration Statement, our ability to manage the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details Asaf Porat +1 800-674-3561 info@appyea.com Company Website http://www.appyea.com

May 16, 2022 07:00 AM Eastern Daylight Time

Funding update: Marquee tech founders and investors join Ultrahuman’s Series A

Ultrahuman

Several prolific tech investors and founders have come together to invest in Ultrahuman, a leading metabolic fitness platform that uses glucose biomarkers to help people optimize their lifestyle. Balaji Srinivasan (ex-Coinbase), Nithin Kamath (founder of Zerodha via Rainmatter) and Preethi Kasireddy (ex-a16z) along with several others have invested in Ultrahuman, the world’s most advanced metabolic fitness platform, in an undisclosed funding amount which will be in addition to their recent series A round. Others influential leaders include Groww founders (Harsh Jain, Lalit Keshre, Neeraj Singh and Ishan Bansal), Razorpay founder, Harshil Mathur and RazorpayX GM - Shashank Mehta, Akshay BD (founding team Uber India) and Tanmay Bhat (celebrity content creator and investor) as they support Ultrahuman, a metabolic fitness platform that helps people optimize their metabolism via real-time biomarkers like glucose in combination with HRV, sleep and activity insights. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome, stress levels, time of the day, food ingredient quality, etc. Ultrahuman launched with Ultrahuman M1 - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day using a continuous glucose monitoring device. It triggers timely personalized nudges to the user such as alerts to high glucose variability events leading to oxidative stress and suggestions to optimize it via lifestyle interventions. Nithin Kamath, founder of Zerodha, added: “A big part of living healthier is tracking your diet and eating right, but the problem is doing this accurately is tricky. The approach that Ultrahuman is taking to tackle this problem of improving metabolic fitness by using biomarkers is really interesting. We're excited to join Mohit and Vatsal on their journey.” Ultrahuman has raised over $25M to date. Existing investors include Alpha Wave, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of other angel investors including Tiger Global’s Scott Schleifer. “We’re super excited to welcome some of the world’s foremost founders, investors and biohackers to join our Series A round. The most inspiring aspect of this investment is that most of them are long term users of the platform as well and that strengthens our mission holistically”. said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). During his training, he observed athletes train smartly via the usage of data, recovery tools and protocols. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

May 12, 2022 06:30 AM Eastern Daylight Time

Image

CoorsTek Recognized as a US Best Managed Company

CoorsTek

CoorsTek is proud to announce it has been selected as a 2022 US Best Managed Company. Sponsored by Deloitte Private and The Wall Street Journal, the program recognizes outstanding U.S. private companies and the achievements of their management teams. The 2022 designees are U.S. private companies that have demonstrated excellence in strategic planning and execution, a commitment to their people and fostering a dynamic, resilient culture, as well as strong financials. This year’s designees continued to propel their businesses forward by prioritizing purpose, investing in their workforces, and demonstrating their commitment to diversity, equity and inclusion. “We are honored to be recognized as a best managed company again this year,” said Jonathan Coors, CEO of CoorsTek. “This award is a tribute to the dedication and resiliency of our CoorsTek team members across the globe over the past several years. It also speaks to the strong values that guide our daily activities and actions, and our focus on delivering essential products and services to the marketplace.” Applicants are evaluated and selected by a panel of external judges focused on assessing hallmarks of excellence in four key areas: strategy, ability to execute, corporate culture and governance/financial performance. They join a global ecosystem of honorees from more than 40 countries recognized by the Best Managed Companies program. About The Best Managed Companies Program The Best Managed Companies program is a mark of excellence for private companies. U.S. designees have revenues of at least $250 million. Hundreds of private companies around the world have competed for this designation in their respective countries through a rigorous and independent process that evaluates four key criteria in their management skills and practices — strategy, execution, culture and governance/financials. U.S. program sponsors are Deloitte Private and The Wall Street Journal. For more information, visit www.usbestmanagedcompanies.com. Please see www.deloitte.com/us/about for a detailed description of our legal structure. About CoorsTek Founded in 1910 and headquartered in Golden, Colorado, CoorsTek is a fifth-generation, family owned and operated global manufacturer of engineered ceramics. By utilizing over half of the world’s known elements in our material formulations, we deliver unique solutions to our diverse customer base by leveraging ceramic properties. With more than 30 facilities across three continents, five million square feet in manufacturing space, and more than 6,000 team members, we are the partner of choice in engineered ceramics. CoorsTek makes the world measurably better by providing customers with amazing solutions, serving customers in numerous industries including semiconductor, aerospace, automotive, medical, energy and many others around the world. For more information about the company and its products please visit our website at www.coorstek.com. Contact Details CoorsTek Nancy Fullerton +1 517-304-4695 nfullerton@coorstek.com Company Website https://www.coorstek.com

May 11, 2022 03:52 PM Eastern Daylight Time

News Release

Exhale CBD Gummies Review: Must-Haves Hemp Edibles To Add CBD Benefits In Your Health

Blue Ribbon Group

CBD is yet another gift from nature to humanity. This naturally occurring chemical is quickly gaining popularity among users for medical and recreational purposes. There are different CBD products on the market, including tinctures, flowers, carts, pre-rolls, gummies, and more. CBD gummies have a unique following across all of the products. They're not only tasty, but they're also good for your health. These are a safe and legal way to lift your spirits and get some much-needed slumber, especially if you're in pain. Several brands provide CBD gummies on the market, but Exhale is frequently considered the best. Exhale sets the bar high by providing products that are authentic and all-natural. In this Exhale's CBD gummies review, we'll delve a little deeper into Exhale and inform you more about the product. Brand Overview: Premium Quality Hemp Gummies Products Exhale Wellness, headquartered in Los Angeles, California, is one of the leading hemp brands in the cannabis market. The brand has manufactured superfoods with the help of the recently discovered cannabinoid for everyone who craves the high and THC. Exhale Wellness' founders had years of experience in the organic food industry and desired to create a similar cannabis product. As a result, they were successful. The firm has now expanded its product portfolio to include Delta 9, HHC, and Delta 8 goods in addition to CBD products. CBD gummies, pre-rolls, carts, and dabs wax are just some of the goods available. The brand's gummies are now considered the best CBD gummies on the market. Exhale CBD gummies are made with hemp grown exclusively in Colorado. Their products are manufactured with the purest ingredients and are free of GMOs, artificial coloring, and unnecessary additives. By purchasing one of their goods, you can ensure that your health will improve, from reducing anxiety and panic attacks to assisting with sleep deprivation. Also, Exhale instills confidence in its clients by having each product tested by a third-party laboratory. This way, they reduce biases through outsourcing testing, ensuring that the results are completely reliable. Exhale Wellness makes all test results available on their website so that you can see them before placing an order. Pros The brand makes a significant investment in research and development Exhale provides effective and safe goods The company offers a variety of goods, including soft gels, edibles, cartridges, flowers, and oils Prompt and courteous customer service There are numerous potencies available Cons The products of Exhale can only be purchased online Benefits Of Exhale Guarantee These products for Exhale come with a satisfaction guarantee, which means that if you're dissatisfied with the results, you can contact the firm and request a refund. Not only does this demonstrate the brand's confidence in the quality of its products, but it also demonstrates that those who place their trust in it can be certain of receiving excellent service. This is especially critical for consumers unfamiliar with CBD products such as these gummies. Transparent Production Policies Exhale is extremely transparent about its manufacturing processes, ingredients, hemp sources, and other business information. It relies on independent laboratory reports to ensure the quality of its products, and all of the items' packaging includes vital information. Customer Feedback Exhale has consistently been ranked and rated the best CBD gummies on the market. Exhale Wellness's clients are typically impressed with the product's quality. The gummies induce a pleasant state of euphoria and alleviate users' health issues and stress, such as joint pain, hypertension, and insomnia. This is why users choose the product because the results are immediate and without negative effects. Variety Of Products Now you may start a business and strike it rich with a single well-received product. However, to be the industry's number one brand, you must manufacture many items without sacrificing quality. Exhale carries a wide variety of Delta 8 and Delta 9 goods, including candies, tinctures, soft gels, vape carts, cigarettes, flowers, and shatters, all of which are guaranteed to be of the highest quality. Additionally, they provide a selection of CBD and HHC-infused items. Natural Ingredients The founders of Exhale Wellness created goods solely from natural resources. The company offers a variety of items, but CBD gummies are particularly popular. On the other hand, Exhale CBD gummies are entirely GMO-free. Exhale has taken the simple joy of eating fruit to a whole new level of potential health benefits. These CBD gummies were created with no artificial flavorings. The taste of these gummies is natural, organic, and calming. Company's Policies The shipping service provided by the organization is lightning fast. Each order is processed within 24 hours demonstrating how rapidly the organization operates. When you make your first purchase from Exhale Wellness, you'll receive a 20% discount and a 30-day money-back guarantee. Almost all of the online Exhale product reviews are from satisfied customers. Vegan And Cruelty-Free Third-party testing revealed that the gummies performed well. It imparts beneficial properties to the gummies without creating any adverse effects. Additionally, these gummies addressed the issue for vegans. These THC gummies are vegan and contain no animal by-products or gluten. This means you can take it regularly, and it comes in a range of tasty natural flavors. Certificate Of Analysis When a corporation tests its product in an independent laboratory for every detail it contains and then publicly shares the results, you know they stand solidly behind their product. It establishes a trusting relationship with each new or returning customer. A certificate of analysis (COA) is a document that provides all of the testing results. And it is freely accessible on the website. Ingredients When you're attempting to alleviate tension and other discomforts, the last thing you need is a lengthy list of anxiety-inducing components you can't even pronounce. That is what you will receive from other brands. Exhale CBD Gummies ingredients contain only pure, potent CBD derived from hemp. Thus, you're ingesting a plant extract to aid in your recovery. It's similar to consuming spinach, but with ingredients that relieve stress and pain in place of Vitamin K. Additionally, when you read the contents list, you will be able to identify and pronounce each element. As a result, you won't add to your stress level by being unaware of what you're putting into your body. Finally, to be clear, Exhale CBD Gummies will not cause you to become intoxicated. Because they do not contain psychoactive THC, they are legal to purchase in all 50 states, regardless of your state's stance on marijuana. This is not weed; it is a relative of the same plant (THC is removed during extraction). Therefore, why wait to test this formula? Who Should Use Exhale Wellness? Exhale products are designed for everyone who wants to enjoy a premium quality hemp product while simultaneously gaining health advantages. The business gives you a ticket to stress-free days. Their natural goods, which have a natural flavor and mild hints of hemp from the terpenes, could be beneficial to your health. These gummies can be taken by anyone who is suffering from anxiety or insomnia. On the Exhale website, there is a wide range of things to choose from, catering to all types of people. The CBD gummies, which have gotten amazing reviews due to their flavor and potency, are the most popular among the public. The CBD gummies formula encourages a natural healing process for chronic ailments, allowing you to live a more active and healthier life. These natural soft gels are easy to chew and digest, as well as being healthful. They start working as soon as it enters the bloodstream. It is free of THC elements because it is uprooted by modern technology and reused after filtration. Factors To Consider While Selecting A CBD Gummy On The Market Full or Broad-Spectrum Opt for products prepared with full or broad-spectrum oil rather than distillate or isolate to reap the entire range of health benefits. Full-spectrum products contained all of the cannabis plant's cannabinoids, including CBD and THC. Broad-spectrum oils contain the majority of cannabinoids but are typically devoid of THC. THC and CBD may act better together than separately according to one source. This is guided to as the entourage effect. Additionally, full-spectrum and broad-spectrum products are less processed, which aids in the preservation of some of cannabis's volatile organic components such as terpenes. Terpenes contribute to its flavor and aroma and have their medical benefits. Exhale CBD gummies are infused with full-spectrum CBD. Product Quality Plants usually imitate their surroundings. For example, coffee has a specific flavor that varies depending on the soil and plants. Organically grown hemp plants have a particularly high absorption capacity. You may have noticed that the flavor of hemp products varies based on their origin. Their surroundings highly influence hemp plants' quality and flavor. This incredible level of absorption, in the right hands, can lead to some unexpected combinations. However, this ability can be problematic, as chemicals and other synthetic components can alter the plant's flavor and taste. This is why it's so important to keep as many organic hemp farms as possible and what it means when a brand claims to be 100% organic. In addition, certain businesses may add additives to their products for various reasons. Several compounds can change the taste, lengthen life, or change the color. Keep an eye on the components they use throughout production because these compounds may negatively affect the final product. It's vital to make sure that the CBD is derived from hemp plants rather than marijuana, as this could lead to legal complications. Brand's Reputation Always consider the brand reputation like Exhale's because a good one ensures that your money is in good hands. Customer reviews, which validate the firm, its product quality, and its services, can gauge its reputation. Never choose a brand unknown to the general public or has no customer evaluations since you may be duped. Even if it isn't a fraud, many brands are likely to employ low-quality components that could harm your health. Safety You are what you eat; therefore, we don't have to say much more if you stuff your body with pesticide CBD gummies that include many toxins. As a result, you should constantly double-check the safety of your products before purchasing them. You may easily do this by keeping an eye out for third-party lab test results. These, among other things, help ensure that the product is free of pollutants and legally compliant. You should not compromise if a brand lacks this. Look in another direction. Aside from that, it would be best if you looked into the ingredients. CBD may not be hazardous to you, but you should be aware of any potential allergies to the product. Before utilizing the best delta-8 THC products, consult your doctor if you have a medical issue. Personal Needs Last but not least, there's the reason you're considering CBD gummies in the first place. Many manufacturers sell gummies for various reasons and applications, but some specialize in certain types of gummies. Clients buy full-spectrum edibles for various reasons, ranging from anxiety to improved focus. Some gummies contain CBD extract or another particular chemical that can aid in treating anxiety and stress management. If you're searching for gummies to help with your mental health, seek CBD products commonly used for that purpose. Benefits Of Consuming CBD Gummies Support Healthy Inflammatory Function The capacity of CBD to support good inflammatory function is likely its most interesting benefit since it can alleviate the unpleasant symptoms of a wide range of human ailments. As a result, considerable research examining CBD's effect on inflammation has been conducted, with promising results even though these studies were mostly conducted on animals. Support For Focus CBD has been demonstrated to interact with dopamine receptors in the body. Dopamine is a natural neurotransmitter that regulates human behavior, including our ability to focus, motivate, remember, and pay attention. Hemp-Less Taste Hemp's flavor isn't for everyone; it's nutty and earthy, and it can turn people off to cannabis in general. As a result, numerous companies provide flavored CBD products to hide hemp's inherent flavor, but people with sensitive taste buds are frequently disappointed. The benefits of CBD gummies are that, because they're made to look like candy, they taste like a pleasant treat with barely any undertones of hemp. It's the ideal solution for individuals who want to get the advantages of CBD but don't want to deal with hemp's naturally strong flavor. How Do Exhale CBD Gummies Work? CBD gummies are probably the simplest way to introduce CBD edibles to your body. Vegan gummies packed with cannabidiol that are naturally extracted and organic might be an excellent method to target your difficulties while also fulfilling your sweet craving. The formula begins by promoting the normal function of the critical receptors found throughout your body. They are highly effective at boosting the ECS system in your body. As a result, you'll notice that everything from pain to inflammation, eating, sleeping, and even cognitive function is under healthy control. Additionally, the natural elements in the formula aid in the healing process associated with common pain and promote bone health. Side Effects According to experts, most people can take up to 1500mg of CBD per day. You'd have to consume roughly 150 gummies to get that much CBD from an ordinary gummy. More gelatine, sugar, and other additives are more likely to induce negative effects than CBD. Large doses of CBD gummies may cause nausea, bloating, and indigestion, among other things. How your body reacts to everything might be from the CBD or the other gummy elements. Even though CBD gummies have no known adverse effects, it's always a good idea to see your doctor before starting any CBD product, as individual results may vary. Especially if you're expecting a child, breastfeeding, have a medical condition or are on any medications. According to a study, most people handle high doses of CBD well and experience few negative effects. A 2017 study showed that CBD was safe, which supports this review. However, according to a 2019 study, CBD may interact with some drugs. It also caused liver damage in mice, according to the study. Overall, research suggests that CBD gummies are safe to consume by anyone, but always consult your doctor before doing so. Who Should Refrain From Exhale Exhale CBD gummies are not intended for use by anybody under the age of eighteen. Exhale CBD gummies are also not suggested for mothers who are breastfeeding. Anyone with a significant medical condition should avoid consuming them. If you've been smoking or drinking, Exhale CBD gummies might not provide the health benefits you're looking for. Dosage CBD gummies are a far more fun way to absorb CBD than capsules or tinctures, and they also contain sugar. Additionally, they are more elegant to consume in public than any of those. As a result, many people enjoy bringing them to work, vacations, and other locations outside the home. Taking a few gummies prior to entering a tense scenario can help you maintain your composure. Bear in mind that it enters your system more slowly than when taking a tincture when you take CBD. Allow at least an hour for thorough absorption if you want it to affect immediately. If you're new to CBD, start cautiously regardless of how wonderful the products are. We recommend beginning with a few gummies daily for a few weeks to assess your body's reaction. You can always add more if necessary. Additionally, gummies can be used in conjunction with other CBD products. If you have a greater need for CBD's natural benefits on that particular day, you can use it as a boost. Where to Buy Exhale's CBD Gummies and Guarantees? You must move quickly if you want to get your hands on this premium, extra-strength, yet inexpensive formula. As previously stated, this product is popular due to its potency and naturalness. It's one of the most popular CBD gummy recipes on the market right now. As a result, you must act quickly if you want to incorporate this into your life. Click any image to go to the Exhale CBD Gummies website to purchase. You'll be able to discover more, obtain the best value, and order directly from the manufacturer this way. The purchasing policy is exceptionally simple for consumers because the payment gateway is lightning fast and instantly confirms the payment, and there is also the option of a monthly subscription. The company asserts that it offers a 30-day money-back guarantee on items returned unopened and in the exact state as when they were sent. Such policies are intended to boost the brand's trust and credibility and assure people that the company is confident in its product claims. => Click here to visit the official website of Exhale wellness What's the Difference Between CBD, Hemp, Cannabis, Marijuana, and THC? Many people still have misconceptions about CBD, believing that cannabis, hemp, marijuana, CBD, and THC (tetrahydrocannabinol) are different. No, they aren't. Cannabis is a type of plant that comes in two different forms: Cannabis Sativa and Cannabis Indica. While both forms of cannabis can make marijuana, hemp is solely produced from the Cannabis Sativa family. This means that, while hemp and marijuana have a few characteristics, there are significant distinctions. The most important is that hemp is nearly devoid of THC, the psychoactive ingredient in marijuana. Indeed, the hemp must contain less than 0.3% THC to be deemed hemp; else, producers face federal prosecution. CBD is the most active ingredient in marijuana, and it does not make you high. Instead, CBD has been credited with reducing anxiety, insomnia, inflammation, and pain. Other studies are being performed to see if CBD can help with Parkinson's illness, schizophrenia, multiple sclerosis, diabetes, and anxiety. Aside from its therapeutic use, hemp is an excellent resource for producing 100% biodegradable, environmentally friendly items such as biofuel, construction materials, clothes, and paper. Can These Gummies Make You High? CBD gummies have no psychoactive components, so that you won't get high from them. CBD is derived from hemp, which has very little THC. Marijuana's psychotropic component is THC. The hemp must have less than 0.3% THC; otherwise, producers risk prosecution under federal law. When it comes to hemp, CBD is the most active component, and CBD does not have any intoxication effects. Instead, CBD has been linked to inflammation, reduced anxiety, sleeplessness, and discomfort, though "linked" does not imply "proved." Is it possible for CBD to have long-term health effects? Because CBD became authorized in the United States in 2018, there aren't enough long-term studies on its effectiveness and side effects to completely address this. The endocannabinoid system, a biological system that helps our bodies find balance, is influenced by CBD. Some members may negatively affect their bodies, acclimate to CBD, and readjust themselves, although these normally fade with time. The occurrence or absence of side effects can be influenced by various factors, including your body chemistry, environmental factors, health conditions, and any drugs you may be taking. As a result, before incorporating CBD into your daily routine, talk to your doctor to determine if it's a suitable fit for you. Drowsiness, nausea, headaches, dry eyes, and dry tongue are common side effects. You're not alone if you're experiencing some of these side effects as you begin your CBD regimen. Some of our members tell us that they experience some adverse effects when they first start using CBD but that the effects usually fade away after a few weeks. Because cannabis can be dehydrating in general, it's critical to water, hydrate, hydrate while commencing a CBD regimen. Is it safe to eat Exhale CBD gummies every day? Yes, you can take these daily. CBD-infused gummies from Exhale are completely safe. You can take these before bedtime every night. This is the optimum time to take this medicine because it encourages sleep. Also, if you're not sure where to begin, talk to a doctor. Start with half a gummy or a single gummy. CBD gummies are also recommended as a post-workout supplement by some experts. They will not hurt you in this situation. Furthermore, if you want to see results, you must stick to your routine. CBD gummies can make you feel more energized and less weary during the day. Thanks to a good night's sleep, you'll wake up feeling more energized than ever. Gummies containing CBD are both healthful and legal to use daily. If you're still not convinced, start taking CBD in this form. Furthermore, you can begin to feel better right soon. You can get your first box of gummies right now from Exhale wellness's website. Is CBD psychoactive? CBD is devoid of tetrahydrocannabinol, the intoxicating component of marijuana. However, it does produce the right amount of exhilaration to assist folks in relaxing and falling asleep. The gummy could knock you out as well if you're not careful. CBD gummies can help you sleep better, but if you're new to them, try with a little amount at first. Some hemp derived products available are potentially dangerous. Only purchase CBD gummies from reputable companies like Exhale to prevent being a victim of these scammers. => Click here to visit the official website of Exhale Wellness Conclusion: Why Consume CBD gummy cubes? That gets us to the end of our Exhale's CBD gummies review. Hopefully, we've provided you with all of the necessary information for your first purchase on their site, relieving you of any anxiety that may arise while exploring their CBD candies online. These gummies provide pain relief and add spice to your life. With all of the fantastic benefits, including top-grade ingredients, third-party lab testing, and customer happiness, it's no surprise that Exhale CBD gummies are becoming increasingly popular. Contact Details Riya Tyagi riya@radrevenue.net

May 11, 2022 07:01 AM Central Daylight Time

Healthcare